39 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
.
Tourmaline also continued to expand its executive leadership team during 2023, including the appointments of Gerhard Hagn as SVP, Head of Commercial
8-K
EX-99.1
TRML
Tourmaline Bio Inc
8 Jan 24
Regulation FD Disclosure
9:19am
transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases
Experienced leadership team 4 Ryan … trial also expected to commence in H2 2024 Accomplished leadership team: extensive experience developing and commercializing antibodies for immune
8-K
EX-99.1
ltwj716yqix4nov5
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
8-K
pkbyx7a98rvch by4
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
425
4ese6y6yte
26 Sep 23
Business combination disclosure
8:24am
8-K
EX-99.1
56ijjar
26 Sep 23
Regulation FD Disclosure
8:21am
424B3
m3xlj
15 Sep 23
Prospectus supplement
6:31am
425
mxygfhl
13 Sep 23
Business combination disclosure
9:14am
8-K
EX-99.1
24ze4s27n 65rb
13 Sep 23
Regulation FD Disclosure
9:13am
S-4/A
51h0g
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
0nfk0i wv66
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
m98re0d8e6l
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-99.2
y2o2jq2ciibxpvmi
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am